Generex Biotechnology Corporation is a Canada-based Company, which develops drug delivery systems and technologies for the treatment of diabetes. The Company has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity. Its buccal insulin spray product, Generex Oral-lyn is in Phase III clinical trials at several sites around the world. The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist device.
|Headquarters||Suite 604, 555 Richmond Street West,|
PO Box 200
TORONTO, ON, Canada M5V 3B1
|Independent Chairman of the Board||John Barratt|
|President, Chief Executive Officer, General Counsel, Director||Mark Fletcher|
|Acting Chief Financial Officer||Stephen Fellows|
|Chief Operating Officer, Secretary||David Brusegard|
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
|Shares Out.||531.5M||Book Value||$-0.02|
|Generex Biotechnology Corp does not pay a dividend.||P/E||--|
|P/Cash Flow (TTM)||--|
*GAAP = prior to non-GAAP analyst adjusted earnings.